Ireland
--:--IST
Recruiting Observational

Longitudinal Study of Gene Expression in the Human Placenta During First-trimester and Full-term Pregnancy at the Single Cell Level

NCT06427408 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-03-25
Last updated
2026-04-03

Condition(s) studied

Pregnancy Related

Investigational drug(s) / intervention(s)

Non applicable

Non applicable: Placental transcriptomic analysis

Study summary

The single nucleus RNA-seq approach allows the placental transcriptome to be analyzed from nuclei, thus preserving the integrity of placental syncytium. This approach is feasible on small fragments of villi and offers for the first time the possibility to consider the characterization of gene expression within the structural unit of the human placenta during pregnancy (at the 1st trimester and childbirth)

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 to 50 * Progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea * Patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics * Patient scheduled for delivery at Port-Royal Maternity Hospital Exclusion Criteria: * Minor patient * Multiple pregnancy * Patient's objection * Without health insurance * Patient under guardianship or curatorship

Primary outcome measure(s)

  • Analysis of the cellular transcriptomic trajectory of the human placenta — Day 0
    Sequencing data will be analysed at the Institut Cochin, cell trajectories will be modelled and intracellular communications will be inferred
  • Analysis of the cellular transcriptomic trajectory of the human placenta — At childbirth
    Sequencing data will be analysed at the Institut Cochin, cell trajectories will be modelled and intracellular communications will be inferred

Trial sites (1)

FacilityCityRegionStatus
Maternité Port-Royal, Cochin hospital Paris IDF Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06427408 on ClinicalTrials.gov ↗ ← All trials in France